SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Sponsor
Sarcoma Alliance for Research through Collaboration
Study ID
NCT02342600
Phase
PHASE2
Status
Withdrawn

Conditions

  • Gastrointestinal Stromal Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pazopanib — DRUG
    A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
  • Trametinib — DRUG
    A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.

Study Details

This study evaluates the combination of trametinib and pazopanib in patients with advanced gastrointestinal stromal tumors (GIST).

Key Dates

Start date
Jan 31, 2017
Status verified
Mar 2017
Primary completion
Jan 31, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Trametinib with Pazopanib
    Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.

Primary Outcome Measure

Disease Control Rate (DCR) [ Time Frame: 16 weeks ]

Related Studies